One current hot topic is ‘pre-exposure prophylaxis’
These results raise thorny questions, going from medical to ethical issues. First, at a time when not all already HIV-infected patients in the world can have access to antiretroviral therapy, is it reasonable to give treatment access to uninfected people for prevention? And will this therapy be reimbursed by the social security system, or be only available to those who can afford it? Secondly, outside the frame of a clinical trial, what is the risk that people use simply the ‘magic protecting bullet’ and give up on condoms? The average efficacy was 44% in the trial, but ranged from 16 only to 63% according to cases. Then, what will be the long-term toxicities of such drug exposure? Finally, the last question is about cost: how to justify a ‘chemical condom’ at $38 a day when condoms themselves cost a few cents each?
This is one of the important topics in terms of public health to be discussed live at the conference. In the meantime, the debate is open between experts, caregivers and community leaders on the conference website.
About the conference:
The Steering Committee contains Professor Jean-François Delfraissy (Director of the French Agency of AIDS Research, Paris, France), Jose Gatell (Barcelona, Spain), Guido Poli (Milano, Italy), Jean-Pierre Routy (Montreal, Canada), Christine Rouzioux (Paris, France), Vicente Soriano (Madrid, Spain), Hans-Jürgen Stellbrink (Hambourg, Germany) and Stefano Vella (Rome, Italy). Website: http://www.isheid.com/
Contact: Alain Lafeuillade, Overcome, Blvd Paul Emile Victor, 92523, Neuilly-sur-
Blvd Paul Emile Victor, 92523
33 (0)1 40 88 97 97